Extrapyramidal side effects with atypical neuroleptics in bipolar disorder

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 30, Issue 2, 2006, Pages 209-213

  Ghaemi, S Nassir ^a,d   Hsu, Douglas J ^b   Rosenquist, Klara J ^b   Pardo, Tamara B ^b   Goodwin, Frederick K ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^d EMORY CLINIC   (United States)

Author keywords

Akathisia; Atypical neuroleptics; Bipolar disorder; Extrapyramidal symptoms; Parkinsonism; Tardine dyskinesia

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; AKATHISIA; ARTICLE; BIPOLAR DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG POTENCY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; MENTAL PATIENT; MULTIPLE REGRESSION; PARKINSONISM; RATING SCALE; RISK ASSESSMENT; TARDIVE DYSKINESIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BIPOLAR DISORDER; DEMOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 33344467623     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2005.10.014     Document Type: Article

References (20)

1. H. Ascher-Svanum, J.S. Kennedy, D. Lee, and M. Haberman The rate, pattern, and cost of use of antiparkinsonian agents among patients treated for schizophrenia in a managed care setting Am. J. Manag. Care 10 2004 20 24
2. Y. Barak, E. Shamir, H. Zemishlani, I. Mirecki, P. Toren, and R. Weizman Olanzapine vs. Haloperidol in the treatment of elderly chronic schizophrenia patients Prog. Neuropsychopharmacol. Biol. Psychiatry 26 2002 1199 1202
3. C.D. Carlson, P.A. Cavazzoni, P.H. Berg, H. Wei, C.M. Beasley, and J.M. Kane An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine J. Clin. Psychiatry 64 2003 898 906
4. M. Dossenbach, A. Erol, M. el Mahfoud Kessaci, M.O. Shaheen, M.M. Sunbol, and J. Boland Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (ic-soho) comparing olanzapine, quetiapine, risperidone, and haloperidol J. Clin. Psychiatry 65 2004 312 321
5. I. Garcia-Cabeza, J.C. Gomez, J.A. Sacristan, E. Edgell, and M. Gonzalez de Chavez Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (efeso study) BMC Psychiatry 1 2001 7
6. A.M. Ghadirian, L. Annable, M.C. Belanger, and G. Chouinard A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients J. Clin. Psychiatry 57 1996 22 28
7. S.N. Ghaemi, F. Soldani, and D.J. Hsu Commentary: evidence-based pharmacotherapy of bipolar disorder Int. J. Neuropsychopharmacol. 6 2003 303 308
8. F. Goodwin, and K. Jamison Manic Depressive Illness 1990 Oxford University Press New York
9. S. Kapur, and J.J. Mann Role of the dopaminergic system in depression Biol. Psychiatry 32 1992 1 17
10. S. Kapur, R. Zipursky, and G. Remington Clinical and theoretical implications of 5ht2 and d2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia Am. J. Psychiatry 156 1999 286 293
11. J.M. Montes, A. Ciudad, J. Gascon, and J.C. Gomez Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study Prog. Neuropsychopharmacol. Biol. Psychiatry 27 2003 667 674
12. M. Ritsner, G. Perelroyzen, H. Ilan, and A. Gibel Subjective response to antipsychotics of schizophrenia patients treated in routine clinical practice: a naturalistic comparative study J. Clin. Psychopharmacol. 24 2004 245 254
13. V. Rodriguez-Perez, A. Lopez, C. Blanco, C. Pena, A. Lopez, A. Abel, Y. Gomez, M. Ferreiro, C. Rego, A. Lopez, F. Cudeiro, V. Alvarez, R. Prieto, and A. Ciudad Olanzapine for the treatment of chronic refractory schizophrenia: a 12-month follow-up naturalistic study Prog. Neuropsychopharmacol. Biol. Psychiatry 26 2002 1055 1062
14. K. Rothman, and S. Greenland Modern Epidemiology 1998 Lippincott-Raven Philadelphia, PA xiii, 737 pp.
15. P. Sachdev The epidemiology of drug-induced akathisia: Part I. Acute akathisia Schizophr. Bull. 21 1995 431 449
16. P. Sachdev, and J. Kruk Clinical characteristics and predisposing factors in acute drug-induced akathisia Arch. Gen. Psychiatry 51 1994 963 974
17. G.S. Sachs, F. Grossman, S.N. Ghaemi, A. Okamoto, and C.L. Bowden Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety Am. J. Psychiatry 159 2002 1146 1154
18. T.L. Schwartz, M. Saba, W. Hardoby, S. Virk, and P.S. Masand Use of atypical antipsychotics in a veterans affairs hospital Prog. Neuropsychopharmacol. Biol. Psychiatry 26 2002 1207 1210
19. M. Tohen, T.G. Jacobs, S.L. Grundy, S.L. McElroy, M.C. Banov, P.G. Janicak, T. Sanger, R. Risser, F. Zhang, V. Toma, J. Francis, G.D. Tollefson, and A. Breier Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The olanzipine hggw study group Arch. Gen. Psychiatry 57 2000 841 849
20. T. Van Putten The many faces of akathisia Compr. Psychiatry 16 1975 43 47